secwatch.observer — SEC 8-K summary
======================================

Issuer:     Damora Therapeutics, Inc. (DMRA)
CIK:        0001800315
Form:       8-K
Filed at:   2023-12-21T23:59:59+00:00
Accession:  0000950170-23-072258
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Galecto reports positive Phase 2a myelofibrosis data; fibrosis reduction in 6 of 10 evaluable patients
--------------------------------------------------------------------------------

- 6 of 10 evaluable myelofibrosis patients on GB2064 monotherapy ≥6 months had ≥1-grade reduction in bone marrow collagen fibrosis.
- All 6 patients with fibrosis reduction maintained stable hematological parameters (hemoglobin, WBC, platelets).
- One patient achieved ≥35% spleen volume reduction; two reduced Total Symptom Score >50%; one had anemia response.
- Four patients entered extension due to clinical benefit; one on treatment >30 months; GI adverse events manageable.
- Company will not decide on further GB2064 trials until completion of strategic alternative process.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1800315/000095017023072258/0000950170-23-072258-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1800315/000095017023072258/glto-20231221.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-072258

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer